Sildenafil
Product Images NDC 68788-7218

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 68788-7218). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Sildenafil Fig1)

A line graph showing mean change from baseline in sitting systolic blood pressure over 24 hours post-dose for Sildenafil 100 mg and placebo in healthy volunteers. The x-axis represents time post dose in hours, and the y-axis shows systolic blood pressure change in mmHg. Sildenafil is marked with circles, placebo with diamonds.*

FDA Label Image

Sildenafil Tablets 100mg Aurobindo (Sildenafil Fig10)

Sildenafil Tablets 100 mg label by Preferred Pharmaceuticals Inc., generic for Viagra. The label states each tablet contains sildenafil citrate equivalent to 100 mg sildenafil. Manufacturer noted as Aurobindo Pharma Limited. Includes storage instructions and caution against transfer of the drug to others. Directions for use include dosing intervals in English and Spanish.*

FDA Label Image

Figure 2 (Sildenafil Fig2)

A line graph titled "Mean Standing Systolic Blood Pressure Change from Baseline" showing changes in systolic blood pressure (mmHg) over time postdose (hours). It compares two groups: Doxazosin with Placebo and Doxazosin with Sildenafil 25 mg, each represented by distinct line styles with markers. The graph tracks blood pressure changes from 0 to 8 hours postdose.*

FDA Label Image

Figure 3 (Sildenafil Fig3)

A line graph showing mean standing systolic blood pressure change from baseline over 8 hours postdose. It compares two groups: Doxazosin with placebo and Doxazosin with Sildenafil 50 mg, with changes plotted on the y-axis in mmHg and time postdose on the x-axis in hours.*

FDA Label Image

Figure 4 (Sildenafil Fig4)

A line graph showing mean standing systolic blood pressure change from baseline over time up to 8 hours after dosing. Two lines compare the effects of Doxazosin with Sildenafil 100 mg versus Doxazosin with placebo, indicating blood pressure trends in mmHg over hours post-dose.*

FDA Label Image

Figure 5 (Sildenafil Fig5)

A line graph illustrating mean Sildenafil plasma concentrations (ng/mL) over time (hours) post dose in healthy male volunteers. The graph shows a peak concentration shortly after administration followed by a gradual decline, representing pharmacokinetic data for a commercial tablet treatment.*

FDA Label Image

Figure 6. Effect Of Sildenafil And Placebo On Maintenance Of Erection By Baseline Score (Sildenafil Fig6)

Two bar charts comparing the effect of Sildenafil and placebo on maintenance of erection by baseline score. Each chart displays percentage of patients at endpoint on the y-axis and baseline score on the x-axis, with bars representing scores from 0 to 5. The top chart shows Sildenafil data, the bottom chart placebo data, illustrating variations across baseline scores.*

FDA Label Image

Sildenafile Fig 7 (Sildenafil Fig7)

Bar chart illustrating the percentage of patients reporting improvement in erections across different treatment groups: Placebo, Sildenafil 25 mg, Sildenafil 50 mg, and Sildenafil 100 mg. The chart shows increasing improvement percentages with higher doses of Sildenafil.*

FDA Label Image

Structure (Sildenafil Str)

Chemical structure of Sildenafil showing its molecular components, including heterocyclic rings, functional groups, and side chains as depicted in the diagram. The structure features a piperazine ring and sulfonamide group characteristic of Sildenafil's chemical composition.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.